

EMA/507523/2015

European Medicines Agency decision

P/0172/2015

of 7 August 2015

on the acceptance of a modification of an agreed paediatric investigation plan for clonidine (hydrochloride) (EMA-001316-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0172/2015

of 7 August 2015

on the acceptance of a modification of an agreed paediatric investigation plan for clonidine (hydrochloride) (EMA-001316-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0074/2013 issued on 26 March 2013,

Having regard to the application submitted by Therakind Limited on 24 March 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 June 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for clonidine (hydrochloride), solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Therakind Limited, 314 Regents Park Road, N3 2JX –London, United Kingdom.

Done at London, 7 August 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/230819/2015 Corr
London, 19 June 2015

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001316-PIP01-12-M01

Scope of the application

Active substance(s):

Clonidine (hydrochloride)

Condition(s):

Sedation

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

Therakind Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Therakind Limited submitted to the European Medicines Agency on 24 March 2015 an application for modification of the agreed paediatric investigation plan as set out in the European Medicines Agency's decision P/0074/2013 issued on 26 March 2013

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 21 April 2015.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.



Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Sedation

2.1.1. Indication(s) targeted by the PIP

Sedation in intensive care

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Measure 1: Development of three different strengths (ready-to-use) vials for intravenous infusion - appropriate for the complete paediatric population.
Non-clinical	0	Not applicable.
Clinical	1	Measure 2: Double blind randomised, multicentre, active controlled trial to evaluate pharmacokinetics, safety and efficacy of Clonidine (Hydrochloride) for sedation in children from birth to less than 18 years of age.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2017
Deferral for one or more measures contained in the paediatric investigation plan:	No